Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab

PURPOSE: Immune checkpoint inhibitors (ICIs) such as nivolumab and ipilimumab (N/I) are important treatment options for advanced renal cell carcinoma (RCC). The tumor microenvironment (TME) in these ICI-treated patients is largely unknown. METHODS: Twenty-four patients treated with N/I between July...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jwa Hoon, Kim, Gi Hwan, Ryu, Yeon-Mi, Kim, Sang-Yeob, Kim, Hyung-Don, Yoon, Shin Kyo, Cho, Yong Mee, Lee, Jae Lyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552830/
https://www.ncbi.nlm.nih.gov/pubmed/36237314
http://dx.doi.org/10.3389/fonc.2022.969569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552830/
https://www.ncbi.nlm.nih.gov/pubmed/36237314
http://dx.doi.org/10.3389/fonc.2022.969569

Ejemplares similares